Wellington Shields Capital Management Llc increased Starbucks (SBUX) stake by 63.78% reported in 2017Q4 SEC filing. Wellington Shields Capital Management Llc acquired 5,300 shares as Starbucks (SBUX)’s stock rose 0.28%. The Wellington Shields Capital Management Llc holds 13,610 shares with $782,000 value, up from 8,310 last quarter. Starbucks now has $83.54B valuation. The stock increased 0.32% or $0.19 during the last trading session, reaching $59.43. About 5.70M shares traded. Starbucks Corporation (NASDAQ:SBUX) has risen 0.40% since April 17, 2017 and is uptrending. It has underperformed by 11.15% the S&P500.
Vivus Inc (VVUS) investors sentiment increased to 0.57 in 2017 Q4. It’s up 0.04, from 0.53 in 2017Q3. The ratio is more positive, as 17 hedge funds started new or increased holdings, while 30 cut down and sold stakes in Vivus Inc. The hedge funds in our database now possess: 25.91 million shares, down from 32.65 million shares in 2017Q3. Also, the number of hedge funds holding Vivus Inc in top ten holdings was flat from 0 to 0 for the same number . Sold All: 9 Reduced: 21 Increased: 9 New Position: 8.
Investors sentiment increased to 1.05 in 2017 Q4. Its up 0.08, from 0.97 in 2017Q3. It increased, as 63 investors sold SBUX shares while 449 reduced holdings. 114 funds opened positions while 423 raised stakes. 983.38 million shares or 1.10% more from 972.68 million shares in 2017Q3 were reported. Hirtle Callaghan Communications Ltd holds 0% or 79 shares in its portfolio. Westpac, a Australia-based fund reported 143,722 shares. Private Ocean Llc has invested 0.03% of its portfolio in Starbucks Corporation (NASDAQ:SBUX). Evercore Wealth Mngmt Lc stated it has 0.06% of its portfolio in Starbucks Corporation (NASDAQ:SBUX). Northstar Gp owns 66,037 shares. North Star Inv Management Corp reported 42,345 shares. Profit Inv Mgmt Ltd Liability Company has 14,925 shares for 0.65% of their portfolio. California State Teachers Retirement System owns 2.36M shares or 0.28% of their US portfolio. West Coast Llc owns 1.82% invested in Starbucks Corporation (NASDAQ:SBUX) for 112,514 shares. 37,968 are owned by Virtu Limited Liability Company. Acadian Asset Mgmt Lc owns 8,252 shares for 0% of their portfolio. Rampart Inv Management Com Ltd Liability Corporation invested in 0.43% or 19,591 shares. Glg Ltd Liability Corporation invested in 0.32% or 76,960 shares. Old Mutual Customised Solutions (Proprietary) Limited holds 0.43% of its portfolio in Starbucks Corporation (NASDAQ:SBUX) for 73,329 shares. Thrivent Financial For Lutherans reported 0.02% of its portfolio in Starbucks Corporation (NASDAQ:SBUX).
Wellington Shields Capital Management Llc decreased Metlife Inc (NYSE:MET) stake by 10,076 shares to 29,776 valued at $1.51 million in 2017Q4. It also reduced Compass Minerals International (NYSE:CMP) stake by 6,780 shares and now owns 16,060 shares. Oneok Inc (NYSE:OKE) was reduced too.
Since January 31, 2018, it had 0 buys, and 3 insider sales for $13.62 million activity. On Tuesday, March 13 WEATHERUP CRAIG sold $3.60M worth of Starbucks Corporation (NASDAQ:SBUX) or 59,838 shares. ULLMAN MYRON E III sold 12,500 shares worth $740,851. The insider BURROWS CLIFFORD sold 162,826 shares worth $9.28M.
Among 37 analysts covering Starbucks Corporation (NASDAQ:SBUX), 23 have Buy rating, 0 Sell and 14 Hold. Therefore 62% are positive. Starbucks Corporation had 105 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Hold” rating by Wedbush given on Friday, July 28. The stock has “Outperform” rating by William Blair on Friday, January 26. The firm has “Hold” rating by Zacks given on Thursday, September 3. Mizuho maintained Starbucks Corporation (NASDAQ:SBUX) rating on Thursday, September 28. Mizuho has “Buy” rating and $75.0 target. The stock of Starbucks Corporation (NASDAQ:SBUX) has “Buy” rating given on Tuesday, October 10 by Cowen & Co. The company was maintained on Thursday, January 25 by Robert W. Baird. The rating was downgraded by Cowen & Co to “Market Perform” on Friday, April 13. Wedbush maintained Starbucks Corporation (NASDAQ:SBUX) on Monday, March 13 with “Outperform” rating. Zacks upgraded the stock to “Hold” rating in Monday, August 24 report. Morgan Stanley maintained it with “Overweight” rating and $67 target in Friday, November 10 report.
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company has market cap of $44.21 million. The firm offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It currently has negative earnings. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension.
Analysts await VIVUS, Inc. (NASDAQ:VVUS) to report earnings on May, 2. They expect $-0.11 EPS, down 1,000.00% or $0.10 from last year’s $-0.01 per share. After $-0.10 actual EPS reported by VIVUS, Inc. for the previous quarter, Wall Street now forecasts 10.00% negative EPS growth.